January 24, 2021

The Niche

Trusted stem cell blog & resources

Center for Regenerative Cell Medicine Arizona

3 min read

  It’s been a busy week for the cellular and regenerative medicine space for COVID-19 news with some possible ups including for Mesoblast and some definite downs. Starting with the more positive media buzz with have Mesoblast. Mesoblast made COVID19 news “Thinly traded Mesoblast Limited (NASDAQ:MESO) rockets 51% premarket on average volume in reaction to its announcement of an 83% (n=10/12) survival rate in ventilator-dependent COVID19 patients who were treated with its allogeneic mesenchymal stem cell product candidate remestemcel-L within the first five days. Nine of the 10 …Read More